American Pharmaceutical Partners (APPX) Adds To Its Broad Oncology Portfolio With The Approval Of Mitoxantrone Injection, USP  
4/12/2006 12:38:37 PM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--April 11, 2006--American Pharmaceutical Partners, Inc. (NASDAQ:APPX - News; APP), a leading specialty injectable pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mitoxantrone Injection, USP (Concentrate), the generic equivalent of Serono Labs' Novantrone®. According to IMS, sales in 2005 of mitoxantrone in the United States exceeded $76 million. APP expects to commence marketing mitoxantrone immediately. APP will sell mitoxantrone in AP-rated bar coded, latex-free vials with TALL man lettering.